Neoadjuvant immune checkpoint inhibitors (ICIs) are standard of care for resectable stage IIIB-D melanoma, but knowledge gaps remain regarding optimal treatment type, long-term survival, postsurgical management and clinical, histopathological or molecular subgroups. We analyzed 1,038 patients treated with neoadjuvant I...
Georgina V. Long, I. Pires da Silva, Kristen A. Perry et al.· Nature Medicine· 0 citations
Tovorafenib demonstrated single-agent clinical activity in solid tumors with BRAF fusions or CRAF fusions or amplification and had a manageable safety profile and may offer a new targeted treatment option for adult patients with tumors harboring these rare genomic driver alterations.
M. Vieito, E. Cabanas, I. Mehmi et al.· JCO Precision Oncology· 0 citations
D dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab were tolerated and preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.
B. Carneiro, Thomas U. Marron, Dmitry Zamarin et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.